D3 Bio
Manufacturing · China · 11-50 Employees
View Company Info for Free
Overview
Headquarters
88 Meiliang Road Mashan St Rm 324, Wuxi,...Website
www.d3bio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About D3 Bio
D3 Bio is a global biotechnology company focused on the discovery, development, and registration of new medicines in oncology and immunology. The company's discovery and development platforms leverage proprietary clinical insight and biomarker strategies to create novel and clinically meaningful therapies for patients in need. D3 Bio's oncology programs target driver mutations or critical immune pathways and are designed to have first-in-class or best-in-class potential. D3 Bio owns global rights for all of its programs.Explore more
D3 Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is D3 Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if D3 Bio has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on D3 Bio recently announced quarterly report
Check out if D3 Bio is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
D3 Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if D3 Bio had a recent Job posting/layoffs
Product Launch: Get notified when D3 Bio launches new products
Funding: Get notified immidiatlly once D3 Bio has new funding data
Congratulate Masked Content for being promoted to Masked Content at D3 Bio
Recommended Actions
Find VP level buyers at D3 Bio
Find more new buyers
Company Profile Activity
Activity Insights
D3 Bio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
D3 Bio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about D3 Bio.
D3 Bio financials insights
Gather financial insights about D3 Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$200M
2024
Series A
$262M
2025
Series B
$108M
D3 Bio Tech Stack
A closer look at the technologies used by D3 Bio
Most Recent Scoops
Funding
Funding
Funding
Funding
Executive Move
Board of Directors
Funding
D3 Bio News & Media
D3 Bio Presents KRAS Pipeline Updates at AACR 2026; Elisrasib (D3S-001), a Next-Generation KRAS G12C Inhibitor, Shows Strong Phase 2 Efficacy Across Multiple Tumor Types
Elisrasib monotherapy demonstrates notable efficacy in three major tumor types at its recommended phase 2 dose (RP2D, 600 mg QD). Phase 2 clinical outcomes include: 2L+ KRAS G12Ci–naïve NSCLC: ORR of 58.8%, mPFS of 12.2 months 2L+ colorectal cancer (CRC): ORR of 46.9%, mPFS of 9.5 months...D3 Bio to Showcase Its Innovative KRAS Pipeline at AACR 2026, Including an Oral Presentation at Clinical Plenary Session
SHANGHAI, March 19, 2026 /PRNewswire/ -- D3 Bio Inc, a global clinical-stage biotechnology company focused on developing transformative oncology therapeutics, is pleased to announce that five abstracts have been accepted for presentation at the upcoming American Association for Cancer...D3 Bio Receives U.S. FDA Clearance for Two IND Applications, Enabling Phase 1 Trial of D3S‑003 and Phase 2 Combination Study of Elisrasib (D3S‑001) with D3S‑002
SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- D3 Bio, a global clinical‑stage biotechnology company focused on developing transformative oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared two Investigational New Drug (IND) applications: D3S‑003 —...Editor's Take: The Week That Was—Dec 8-13 - DealStreetAsia
Startup funding to private market investments and trends, catch the week's top headlines.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding D3 Bio
Sign Up For FreeTo access detailed company insights
D3 Bio is a global biotechnology company focused on the discovery, development, and registration of new medicines in oncology and immunology. The company's discovery and development platforms leverage proprietary clinical insight and biomarker strategies to create novel and clinically meaningful therapies for patients in need. D3 Bio's oncology pro... Read More
